

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_76639
Title of the Manuscript:	UBROGEPANT –A REVIEW
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	<p>1.The authors described their trial as open-label and then mentioned the drug was given blindly, how it was blinded and by whom?</p> <p>2.How the diagnosis of migraine was done in this study?</p> <p>3. The mentioned study population is 1230 but when collecting the number of the groups (404 as Ubrogepant 50 mg, 409 as Ubrogepant 100 mg and 419 as control) the total is 1232 not 1230.</p> <p>4. Why the authors did not use another arm taking Telcagepant for comparison with the safety and efficacy of Ubregepant?</p> <p>5. There is no description of any details regarding the efficacy and the reported adverse events in each arm in the study. Was this difference significance or not? the percent of improvement and the percent of hepatotoxicity and its pattern in each arm is not clear at all.</p> <p>6.In patients with hepatic impairment the authors mentioned the drug requires dose adjustment although they mentioned it has lower risk of hepatotoxicity..who is the hepatic patient that requires this adjustment?</p> <p>7. For geriatric population the authors mentioned the dose should be altered to the lower doses..at what age this is applied? and what is the lower dose?</p>	
<u>Minor</u> REVISION comments	<p>Give examples of the CYP3A4 inhibitor drugs that is known to interact with ubregepant</p>	
<u>Optional/General</u> comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<p><i>(If yes, Kindly please write down the ethical issues here in details)</i></p>	

Reviewer Details:

Name:	Haidi Karam-Allah Ramadan
Department, University & Country	Assiut University, Egypt